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Abstract: 
 
Current chemotherapeutic dosing strategies are limited by the toxicity of anticancer agents and 
therefore rely on multiple low-dose administrations. As an alternative, we describe a novel 
sustained-release, biodegradable polymeric nanocarrier as a single administration replacement of 
multi-dose paclitaxel (PTX) treatment regimens. The first synthesis of poly(1,2-glycerol 
carbonate)-graft-succinic acid-paclitaxel (PGC–PTX) is described, and its use enables high, 
controlled PTX loadings of up to 74 wt%. Moreover, the polymer backbone is composed of 
biocompatible building blocks—glycerol and carbon dioxide. When formulated as nanoparticles 
(NPs), PGC–PTX NPs exhibit PTX concentrations >15 mg mL−1, sub-100 nm diameters, narrow 
dispersity, storage stability for up to 6 months, and sustained and controlled PTX release kinetics 
over an extended period of 70 days. A safely administered single dose of PGC–PTX NPs 
contains more PTX than the median lethal dose of standard PTX. In murine models of peritoneal 
carcinomatosis, in which the clinical implementation of multi-dose intraperitoneal (IP) treatment 
regimens is limited by catheter-related complications, PGC–PTX NPs exhibit improved safety at 
high doses, tumor localization, and efficacy even after a single IP injection, with comparable 
curative effect to PTX administered as a multi-dose IP treatment regimen. 
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Current chemotherapeutic dosing strategies are limited by the toxicity of anticancer agents and therefore
rely on multiple low-dose administrations. As an alternative, we describe a novel sustained-release,
biodegradable polymeric nanocarrier as a single administration replacement of multi-dose paclitaxel
(PTX) treatment regimens. The first synthesis of poly(1,2-glycerol carbonate)-graft-succinic acid-
paclitaxel (PGC–PTX) is described, and its use enables high, controlled PTX loadings of up to 74 wt%.
Moreover, the polymer backbone is composed of biocompatible building blocks—glycerol and
carbon dioxide. When formulated as nanoparticles (NPs), PGC–PTX NPs exhibit PTX concentrations
>15 mg mL1, sub-100 nm diameters, narrow dispersity, storage stability for up to 6 months, and
sustained and controlled PTX release kinetics over an extended period of 70 days. A safely administered
single dose of PGC–PTX NPs contains more PTX than the median lethal dose of standard PTX. In murine
models of peritoneal carcinomatosis, in which the clinical implementation of multi-dose intraperitoneal
(IP) treatment regimens is limited by catheter-related complications, PGC–PTX NPs exhibit improved
safety at high doses, tumor localization, and efficacy even after a single IP injection, with comparable
curative effect to PTX administered as a multi-dose IP treatment regimen.Introduction
Cancer continues to be one of the leading causes of mortality
worldwide.1,2 While cytotoxic chemotherapeutics are a mainstay
in the treatment of cancer, the optimization of dosing schedules
remains a challenge due to the relatively low therapeutic index
of many antineoplastic agents.3,4 In fact, the dosing of an anti-
cancer agent is typically determined in a phase 1 study, in which
the end-point is dose-limiting toxicity rather than efficacy.
Although continuous multi-day infusion improves the thera-
peutic index of several chemotherapeutics, its implementation
remains challenging, especially in the local treatment of peri-
toneal cancers.4–6 Additionally, control of both drug level and
duration of treatment is difficult to achieve via currentd Chemistry, Boston University, Boston,
en's Hospital, Boston, MA 02215, USA.
stry, University of North Carolina at
men's Hospital, Boston, MA 02215, USA
tion (ESI) available. See DOI:
hemistry 2017intermittent bolus dosing. Thus, alternative delivery strategies,
especially those that are safe and facile to implement (i.e., single
administration), are of signicant interest.
Nanoparticle (NP) drug delivery systems possess several
advantages over conventional small molecule chemotherapeu-
tics.7–15 Such nanocarriers enhance the delivery of hydrophobic
agents, and afford controlled and sustained drug release,
thereby increasing the efficacy of many anticancer agents in
preclinical animal models. Importantly, NP drug delivery
systems provide an opportunity to enhance chemotherapeutic
dosing by enabling the safe delivery of higher doses of anti-
cancer agents—a topic underexplored in the area of nano-
medicine. Of note, one of the advantages of albumin-bound
(nab-) paclitaxel (PTX) ABI-007 (Abraxane) is the ability to
safely administer doses 70% greater than the PTX standard of
care.16 Polymeric NPs, in particular, demonstrate signicant
advantages as a result of their solid nature.11,17 However, poly-
meric carriers with physically entrapped agents suffer from low
drug loading and signicant burst release.18 Alternatively,
polymer–drug conjugate NPs minimize or eliminate the
problem of burst release, while additionally providing the
ability to incorporate drugs at high, predened loadings with
specically engineered release kinetics.11,19,20Chem. Sci., 2017, 8, 8443–8450 | 8443
Fig. 1 Synthesis and formulation of PGC–PTX NPs. (a) PGC is
synthesized by the copolymerization of benzyl glycidyl ether with CO2
followed by debenzylation hydrogenation. PGC is then grafted with
succinic acid and PTX to afford PGC–PTX conjugate. (b) PGC–PTXNPs
are formulated by emulsifying the polymer in the presence of sodium
dodecyl sulfate (SDS).
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View Article OnlinePTX is one of the most widely used chemotherapeutic agents
for a variety of solid malignancies, including lung, pancreatic,
ovarian, breast, and peritoneal mesothelioma. Despite its
widespread use, PTX dosing is sub-optimal due to its low ther-
apeutic index, poor solubility, rapid systemic clearance, and
limited tumor exposure.21–23 As a result of its poor aqueous
solubility (0.3 mg mL1), PTX is commonly delivered in a cre-
mophor EL/ethanol (1 : 1 v/v; C/E) excipient, which is known to
cause adverse side-effects and severe hypersensitivity reac-
tions.24,25 Thus, alternative delivery methods are of keen
interest. Currently under clinical investigation, a water-soluble
macromolecular poly(L-glutamic acid)–PTX conjugate (PTX
poliglumex) increases PTX solubilization (9 mg mL1) while
exhibiting an improved safety prole and enhanced tumor
exposure compared to PTX-C/E.26 Previously, polymer–PTX
conjugate NP delivery systems have demonstrated high loading
capacities (5–65 wt%), improved PTX aqueous concentrations,
and controlled and sustained PTX release kinetics for up to 10
days.19,20,27–32 However, systems that deliver PTX over prolonged
periods of time are lacking.
Motivated by these ndings, we herein report the rst example
of a nanocarrier in which PTX is incorporated at high, controlled
loadings of up to 74 wt%, and in which PTX concentrations are
improved by >50 000 fold (>15 mg mL1) compared to PTX solu-
bility in aqueous solution. Reducing carrier material and maxi-
mizing drug content (i.e. optimizing drug/material efficiency)
departs from the majority of PTX drug carriers which typically
achieve <10 wt% drug loading, and therefore require the admin-
istration of large amounts of carrier material to achieve a given
dose. Moreover, we use poly(1,2-glycerol carbonate) (PGC) as the
novel polymer scaffold for PTX attachment as the PGC backbone is
readily degradable and biocompatible, consisting of only glycerol
and carbon dioxide.33,34 For this reason, polymers based on glyc-
erol are of signicant interest for drug delivery, tissue engineering,
and tissue coating applications.35–38 The polymer's functionaliz-
able pendant primary hydroxy provides a site for PTX conjugation
via a succinic acid linker in order to give poly(1,2-glycerol
carbonate)-gra-succinic acid-paclitaxel (PGC–PTX). We demon-
strate that PGC–PTX NPs possess sub-100 nm diameters, narrow
dispersity, high storage stability, sustained and controlled release
kinetics, tunable in vitro potency, improved in vivo safety at high
doses, in vivo intraperitoneal (IP) tumor localization, and in vivo
efficacy even aer a single IP injection.
Results and discussion
PGC is synthesized via the alternating copolymerization of
epoxide and carbon dioxide, followed by high pressure hydro-
genolysis to remove the benzyl group, as previously described
(Fig. 1a).33 This metal catalyzed copolymerization reaction is
versatile, efficient, and amenable to a large number of epoxide
monomers.39–41 PGC is then treated with succinic anhydride and
4-dimethylaminopyridine (DMAP) to give poly(1,2-glycerol
carbonate)-gra-succinic acid (PGC-g-SA). Standard coupling
chemistry using N,N0-dicyclohexylcarbodiimide (DCC) and
DMAP with PTX affords PGC–PTX with high PTX loadings of up
to 70 mol%, or 74 wt%. PTX is linked to the polymer backbone8444 | Chem. Sci., 2017, 8, 8443–8450via hydrolysable ester linkages. PTX incorporation in molar
ratio is determined via 1H NMR by integrating the peaks that
correspond to the methine proton on the polymer backbone
and the C20 proton on the PTX side chain. To elucidate the site
of PTX functionalization, PTX and SA were coupled using
DMAP, and the PTX–SA conjugate was isolated by ash column
chromatography. Using 1H NMR, we determined that PTX binds
SA at its C20-OH as indicated by the downeld chemical shi of
the CH proton on C20 from 4.79 to 5.51 ppm (Fig. S2†). Conju-
gating PTX at the C20-OH, which is critical for its activity,42,43
confers control over the biological activity of the conjugate by
necessitating the additional cleavage of PTX into its active form.
To study the effect of PTX loading on NP behavior, we focus our
evaluation on PGC–PTX with 34, 39, and 43 mol% PTX incor-
poration (i.e., 34, 39, and 43% PGC–PTX; 58, 61, and 64 wt%
PTX respectively) as these polymers are reproducibly synthe-
sized with high PTX incorporation efficiencies of >80%, and
form monodisperse NPs of equal size. By size exclusion chro-
matography, the PGC–PTX constructs used are 9–13 kDa, with
polydispersity indices (PDIs) between 1.3 and 1.6 (Table S1†).
It has been previously demonstrated that sub-100 nm parti-
cles exhibit effective tumor tissue penetration and retention,
while sub-50 nm NPs exhibit poor tumor retention.7,44,45
Therefore, a diameter of 50–100 nm was targeted for the PGC–
PTX nanocarriers. PGC–PTX NPs are prepared using a mini-
emulsion synthesis procedure in which the surfactant, sodium
dodecyl sulfate (SDS), is dissolved in phosphate buffer and
added to a polymer–dichloromethane solution at a 1 : 5This journal is © The Royal Society of Chemistry 2017
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View Article Onlinesurfactant : polymer mass ratio (Fig. 1b). The mixture is then
emulsied under an argon blanket via ultrasonication, and the
colloid is puried by dialysis. Dynamic light scattering (DLS)
and scanning electronmicroscopy (SEM) indicate the formation
of monodisperse sub-100 nm NPs (Fig. 2a and b). PGC–PTX NP
size, PDI, and zeta potential (Fig. 2a, c and d) do not vary with
PTX loading. However, drug-free NPs composed of poly(benzyl
1,2-glycerol carbonate) (PGC–Bn), the PGC polymer prior to
deprotection, exhibit slightly smaller diameters (63.7  7.6 nm)
and greater dispersity (0.126  0.043). The 34, 39, and 43%
PGC–PTX NPs possess average diameters of 77.9  9.8 nm, 77.5
 5.2 nm, and 82.9 4.8 nm, and PDIs of 0.078 0.034, 0.080
0.028, and 0.080  0.035, respectively. All NPs exhibit similar
zeta potentials between 43 and 51 mV due to the negative
charge of the SDS surface coating. Using current formulation
parameters, NP solutions with markedly high PTX concentra-
tions >15 mg mL1 are prepared, compared to PTX aqueous
solubility of 0.3 mg mL1.46 The high concentrations of PTX
achieved using PGC–PTX NPs thus eliminate the need for
additional solubilizing agents such as C/E, while simulta-
neously reducing carrier material due to high PTX
incorporation.
Among the challenges impeding the translation of nano-
medicines into clinical practice are batch-to-batch variation, high
dispersity, and poor storage stability.47 Having demonstrated that
the PGC–PTX NP formulation is robust and reproducible, and
that PGC–PTX NPs exhibit narrow dispersities, we next evaluated
NP storage stability. The 39% PGC–PTX NPs were used for anal-
ysis as a representative population, as this formulation has the
median drug loading among the NPs evaluated. The NPs were
stored in solution at 4 C, or lyophilized and stored at 20 C,
without the addition of any stabilizing agents. At later time-
points, lyophilized NPs were resuspended in phosphate buffer
and both sets of NPs were evaluated for NP size as well as
unconjugated PTX content via DLS and high performance liquid
chromatography (HPLC), respectively. Over the course of 180
days, PGC–PTX NPs maintain a stable diameter of 77–88 nmFig. 2 Characterization of PGC–PTX NPs. (a) DLS size measurements
of drug free PGC–Bn NPs and PGC–PTX NPs with varying PTX load-
ings in mol%. (b) SEM micrograph of PGC–PTX NPs. (c) Polydispersity
indices and (d) zeta potentials of PGC–Bn and PGC–PTX NPs as
measured by DLS. Data is presented as mean standard deviation of 3
independently formulated NP batches per group.
This journal is © The Royal Society of Chemistry 2017(Fig. 3a), and free/unconjugated PTX content remains constant at
1–2% of total PTX loading (Fig. 3b). Additionally, resuspended
NPs do not differ in size or free PTX content from NPs stored in
solution. SEM micrographs conrm the presence of stable NPs
aer 90 and 180 days of storage (Fig. 3c–f). Taken together, these
results demonstrate that PGC–PTX NP physicochemical charac-
teristics are not altered under storage conditions for up to 6
months.
To characterize PTX release kinetics as well as the effect of
drug loading, 34% and 43% PGC–PTX NPs were incubated in pH
7.4 phosphate buffer for 70 days at 37 C (Fig. 3g and h). At given
time-points, samples were withdrawn from the release media and
free PTX content was determined via liquid chromatography-
mass spectrometry (LC-MS). At early time-points (<10 days), PTX
release is slightly accelerated in 34% PGC–PTX NPs compared to
43% PGC–PTX NPs (Fig. 3g). At later time-points (>10 days), PTX
cumulative release is comparable for both formulations (Fig. 3h).
An initial burst release is not observed, consistent with release
being dependent on both diffusion and cleavage of the drug from
the polymer backbone. Furthermore, PGC–PTX NPs exhibit
controlled and sustained drug release kinetics, with 70% and 63%Fig. 3 PGC–PTX NP storage stability and release kinetics. PGC–PTX
NPs were stored in solution at 4 C or lyophilized, stored at 20 C,
and resuspended at given time-points. (a) NP diameter and (b) free/
unconjugated PTX content were evaluated over the course of 6
months of storage. SEM micrographs of NPs stored as (c, e) a solution
or as (d, f) a lyophilized powder after (c, d) 90 and (e, f) 180 days of
storage. PTX release kinetics from 34% and 43% PGC–PTXNPs at 37 C
in 0.3% SDS pH 7.4 phosphate buffer at (g) early time-points (<10 days)
and over (h) 70 days. All experiments were performed in triplicate, with
data presented as mean  standard deviation.
Chem. Sci., 2017, 8, 8443–8450 | 8445
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View Article Onlinecumulative PTX release aer 70 days for 34% and 43% PGC–PTX
NPs, respectively.
In vitro NP cytotoxicity was evaluated aer 5 days of treat-
ment in several human cancer cell lines: MSTO-211H meso-
thelioma cancer cells (Fig. 4a), A549 lung cancer cells (Fig. 4b),
and PANC-1 pancreatic cancer cells (Fig. 4c). By conjugating
PTX to SA at the C20-OH position critical for PTX activity, we
reduce the in vitro potency of PTX–SA-C/E relative to PTX-C/E by
requiring the additional cleavage of PTX into its active form.
Similarly, due to the continuous and sustained release of PTX
from the NP formulations, PGC–PTX NPs exhibit lower in vitro
potency compared to PTX-C/E (Fig. 4 & Table S2†). A robust
correlation between the 50% inhibitory concentration (IC50)
and drug content suggests that PTX release rates decrease as
polymer drug content is increased. This result is in agreement
with the measured release kinetics, which indicate that at early
time-points (<10 days), drug release is slightly accelerated in
34% PGC–PTX NPs relative to 43% PGC–PTX NPs. Due to the
hydrophobic nature of PTX itself, PGC–PTX NPs with higher
PTX loadings may exhibit reduced cleavage and release rates
owing to less water penetration into the polymer core. Addi-
tionally, the increase in molecular weight resulting from higher
drug incorporation may result in more compact polymer
aggregation in the NP core, further contributing to reduced PTX
release. These ndings are consistent with those reported by
others investigating PTX conjugate polymeric nano-
assemblies.19,30–32 Cells treated with drug-free PGC–Bn NPs at
equivalent PGC backbone concentrations to 34% PGC–PTX NPs
exhibit minimal cell death. However, the reduction in cell
viability at high concentrations of PGC–Bn NPs is potentially
due to the toxicity of the SDS surface coating (Fig. S7†). None-
theless, the maximum concentration of SDS used in the treat-
ment of cells in vitro is 1.8 mg mL1, which is below the range of
previously reported IC50 values (43–127 mg mL
1).48–50
To evaluate NP cellular internalization, a uorescent
rhodamine-labeled PGC–PTX polymer (PGC–PTX-Rho; 10 mol%Fig. 4 Activity of PGC–PTXNPs against cancer cells in vitro. (a) MSTO-
211H, (b) A549, and (c) PANC-1 cells were treated with PGC–PTX NPs
with varying PTX loadings in mol%, PTX-C/E, PTX–SA-C/E, or drug-
free PGC–Bn NPs (given at equivalent PGC backbone concentrations
to 34% PGC–PTX NPs). Cell viability was assessed after 5 days of
treatment. All experiments were performed in triplicate, with data
presented as mean  standard deviation.
8446 | Chem. Sci., 2017, 8, 8443–8450Rho, 40 mol% PTX) was synthesized by rst reacting PGC with
rhodamine B isothiocyanate and proceeding with the reaction
as previously described to conjugate SA and PTX. PGC–PTX-Rho
NPs are formulated in the same manner as PGC–PTX NPs and
are physically similar, with a diameter of 78.8 8.0 nm, a PDI of
0.101  0.059, and a zeta potential of 43  8 mV. The
maximum dose of PGC–PTX-Rho NPs that can be administered
without inducing cell death was determined by evaluating
MSTO-211H cell viability 24 h aer treatment with 40% PGC–
PTX NPs. Given that cell viability exceeds 95% at PTX doses
#100 ng mL1 (Fig. S8†), MSTO-211H cells were treated with
PGC–PTX-Rho NPs at a dose of 100 ng mL1 PTX, and cellular
internalization kinetics were assessed via ow cytometry at
various time-points aer treatment (Fig. 5a and b). The increase
in uorescence intensity over time indicates an increase in the
portion of the cell population which internalized NPs (Fig. 5a).
To quantitate internalization, positive cells were dened as cells
which exhibit higher uorescence than 99% of the control/
untreated population (Fig. 5b). PGC–PTX Rho NP internaliza-
tion occurs rapidly, with >75% of the cell population taking up
NPs aer 4 h of treatment, and nearly all cells exhibiting NP
internalization following 24 h of treatment. PGC–PTX-Rho NP
internalization, rather than cell surface adhesion, was
conrmed aer 24 h of treatment via confocal microscopy
(Fig. 5c). These results are in agreement with previous studies
reporting the internalization of negatively charged NPs.51–54
Since PGC–PTX NPs contain a substantial quantity of PTX
but release their payload gradually and continuously, we
hypothesized that PGC–PTX NPs can be safely administered atFig. 5 Cellular internalization of PGC–PTX-Rho NPs. Uptake of PGC–
PTX-Rho NPs was measured over time in MSTO-211H cells using flow
cytometry. (a) A sample set of histograms shows increased fluores-
cence intensity of the cell population over time. (b) Positive cells are
defined as cells which exhibit higher fluorescence than 99% of the
control/untreated population. Data presents mean  standard devia-
tion of three individual experiments. (c) Laser-scanning confocal
microscope image of MSTO-211H cells after 24 hours of incubation
with PGC–PTX-RhoNPs. Image presented is the 2-D projection of a 3-
D, 6 mm z-stack. Orthogonal views are shown on the periphery. Cell
membranes are visualized in green, nuclei in blue, and NPs in red.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinesignicantly higher PTX doses than standard PTX-C/E. For
reference, the maximum tolerated dose (MTD) of PTX-C/E in
mice by IP administration is reported between 13–50 mg kg1,
while the median lethal dose (LD50) is 128 mg kg
1.55–58 To test
this hypothesis, an approved pilot trial was constructed with
IACUC guidance, and healthy mice were given 34% PGC–PTX
NPs via a single IP injection at a dose of 140 mg kg1 PTX. The
34% PGC–PTX NP formulation was chosen for in vivo evaluation
given its superior in vitro efficacy. Aer treatment with 34%
PGC–PTX NPs, mice do not exhibit any signs of acute or chronic
toxicity and maintain healthy body weight (Fig. S9a†). All of the
mice were euthanized 120 days aer treatment, and tissue was
harvested for histological analysis to evaluate organ toxicity.
Histological evaluation of major organs conrms that the
treatment is well tolerated compared to untreated controls
(Fig. S9b–m†).
Encouraged by these results, we evaluated the efficacy of PGC–
PTX NPs as a single dose in murine models of peritoneal meso-
thelioma. Mortality in patients with peritoneal mesothelioma
commonly results from local disease progression with median
survivals of only 4–12 months post-diagnosis.51,59 Although long-
term regional chemotherapy has demonstrated improved
outcomes in patients with peritoneal carcinomatosis, its imple-
mentation is limited by catheter-related toxicities and intoler-
ance.5,6 Thus, the optimization of long-term IP chemotherapeutic
dosing continues to be of clinical interest. We hypothesized thatFig. 6 In vivo peritoneal distribution and efficacy of PGC–PTX NPs as a si
(a) rhodamine or (b) PGC–PTX-Rho NPs at equivalent rhodamine doses
ambient and (right) ultraviolet light. The largest IP tumors are circled in ye
of tumor under ultraviolet light. PGC–PTX NP efficacy was evaluated in a
animals (n ¼ 8/group) received MSTO-211H-luc cells followed by same-
treated with PGC–Bn NPs, 20 mg kg1 PTX-C/E, daily 20 mg kg1 PTX-C
PTX via 34% PGC–PTX NPs. PGC–PTX NP efficacy was also evaluated in
survival and (f) tumor burden of animals treated with saline, PGC–Bn NPs
PGC–PTX NPs. Bioluminescence data is presented as the mean  stand
This journal is © The Royal Society of Chemistry 2017a single, high-dose PGC–PTX NP IP injection will leverage the
utility of the IP route of administration, while exhibiting equiva-
lent efficacy to a multi-dose PTX treatment regimen due to its
sustained release prole.
First, to determine NP distribution within the peritoneal
cavity, mice received an IP injection of either PGC–PTX-Rho NPs
or rhodamine in saline three weeks aer IP MSTO-211H tumor
inoculation. Three days aer injection, animals were euthanized,
and the peritoneum was assessed under ambient and ultraviolet
light. By gross inspection, NPs are visualized primarily in areas of
tumor, suggesting that PGC–PTX NPs preferentially localize to IP
tumors following local administration (Fig. 6a and b). This
observation is consistent with previous reports on the localization
of negatively charged NPs to peritoneal tumors following IP
administration, and may be attributed to the increased metabolic
activity and more rapid NP internalization of tumor cells
compared to healthy cells.51,59–61 Quantitative and mechanistic
studies exploring this phenomenon are underway, including the
evaluation of the distribution and localization of uorescently-
labeled, non-drug loaded PGC NPs.
We next evaluated the efficacy of PGC–PTX NPs in preventing
the establishment of mesothelioma locally in the peritoneum.
Immediately following IP tumor inoculation with luciferase-
expressing MSTO-211H (MSTO-211H-luc) cells, animals
received one of several treatments via separate IP injection.
Treatment groups included a single dose of 140 mg kg1 PTX asngle dose. Three weeks after IP tumor inoculation, mice received either
. Three days after injection, the peritoneum was assessed under (left)
llow in each image. PGC–PTX-Rho NPs are visualized primarily in areas
prevention of peritoneal mesothelioma establishment model in which
day treatment. (c) Cumulative survival and (d) tumor burden of animals
/E for 7 days, weekly 20 mg kg1 PTX-C/E for 7 weeks, or 140 mg kg1
the treatment of established peritoneal mesothelioma. (e) Cumulative
, weekly 20 mg kg1 PTX-C/E for 7 weeks, or 140 mg kg1 PTX via 34%
ard deviation for 3 randomly assigned animals per group.
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View Article Online34% PGC–PTX NPs, PGC–Bn NPs (polymer backbone control),
20 mg kg1 PTX-C/E (single PTX dose control), 7  20 mg kg1
daily PTX-C/E (total dose control), and 7  20 mg kg1 weekly
PTX-C/E (total dose control). Given the known lethality of
a bolus dose of 140 mg kg1 PTX-C/E, this positive control could
not be justied, and therefore, equivalent PTX dose compari-
sons were achieved with seven injections of 20 mg kg1 PTX-C/E
at daily or weekly dosing intervals. Nonetheless, animals that
received 7 daily doses of 20 mg kg1 PTX-C/E exhibit a 63%
acute mortality rate due to PTX-C/E toxicity (Fig. 6c). Conversely,
when the equivalent PTX-C/E dose is administered over seven
weeks, acute toxicity is decreased and animals exhibit compa-
rable survival to those receiving a single dose of 140 mg kg1
PTX via PGC–PTX NPs (median survivals of 76 and 86.5 days,
respectively; p ¼ 0.77). Similarly, at 4 and 6 weeks aer tumor
inoculation, PGC–PTX NP treated animals exhibit comparable
tumor burden to animals treated with a weekly PTX-C/E multi-
dose regimen (Fig. 6d). Therefore, a single high dose of PTX
can be safely administered via PGC–PTX NPs without the risk of
C/E hypersensitivity or other toxicities, and with comparable
efficacy to PTX-C/E administered as a multi-dose regimen over
the course of weeks.
To determine whether these ndings are replicated in an
established model of peritoneal mesothelioma, animals were
treated one week aer tumor inoculation with either saline,
PGC–Bn NPs (polymer backbone control), or 140 mg kg1 PTX
administered as a single dose of 34% PGC–PTX NPs or as 7 
20 mg kg1 weekly PTX-C/E (total dose control). Consistent with
our previous ndings, animals treated with PGC–PTX NPs or 7
weekly PTX-C/E exhibit similar tumor burden at 4 and 6 weeks
aer tumor inoculation, and overall survival is comparable
between PGC–PTX NP and 7  20 mg kg1 weekly PTX-C/E
groups (median survivals of 55 and 65 days, respectively; p ¼
0.80) (Fig. 6e and f). Due to their improved safety prole and
sustained PTX release kinetics, PGC–PTX NPs can therefore
supplement chemotherapeutic dosing as a safe and facile
replacement for multiple PTX-C/E administrations.
Conclusions
The conjugation of small molecule anticancer agents to poly-
meric carriers is a promising approach for overcoming the
clinical limitations of cytotoxic chemotherapeutics. The
progression of PTX poliglumex into clinical evaluation high-
lights the potential of this approach to improve patient
outcomes. Nonetheless, several key features distinguish PGC–
PTX NPs from PTX poliglumex. First, PGC–PTX NPs are
a colloidal drug delivery system, whereas PTX poliglumex is
a linear, water-soluble polymer–drug conjugate. The formula-
tion of the hydrophobic PGC–PTX polymer into colloidal NPs
affords high drug loadings of up to 74 wt%. Since PTX poli-
glumex relies on the improved aqueous solubility afforded by
the poly-L-glutamic acid backbone, PTX loading is limited to
37 wt%.26 Additionally, the hydrolytic release of PTX from PTX
poliglumex occurs at a rate of approximately 12% per day, with
most of the drug being released within 8 days.62 On the contrary,
PGC–PTX nanocarriers exhibit controlled and sustained drug8448 | Chem. Sci., 2017, 8, 8443–8450release over an extended period of 70 days, with <15% of the
drug being released over an 8 day period. Although both
systems employ an ester linkage between the drug and the
carrier, the signicant difference in release kinetics is likely due
to the sequestration of PTX within the hydrophobic core of the
PGC–PTX NP, which is not achieved in the water-soluble PTX
poliglumex. The extended drug release exhibited by PGC–PTX
NPs enables their use as a single, high-dose replacement for
multi-dose PTX treatment regimens, especially for the treat-
ment of peritoneal cancers, in which the implementation of
local, multi-dose treatment regimens is challenging. While
a previously published report illustrates the utility of single,
high-dose PTX poliglumex in the local treatment of peritoneal
cancers relative to multi-dose PTX regimens, PTX-treated
animals received signicantly lower total drug (15–60 mg kg1
PTX given over 3 administrations) compared to animals treated
with PTX poliglumex (140–200 mg kg1 PTX equivalent), con-
founding a direct comparison between the two treatment
groups.63
In summary, our work presents the rational design of
a biodegradable polymeric nanocarrier in which PTX is incor-
porated at high, controlled loadings of up to 74 wt% and in
which PTX aqueous concentrations exceed 15 mg mL1.
Importantly, PGC presents a generalizable platform for the
controlled conjugation and delivery of other therapeutic or
imaging agents. The PGC–PTX NP formulation is robust,
producing monodisperse sub-100 nm NPs with long-term
storage stability and sustained PTX release kinetics. Due to
the controlled and sustained release of PTX, PGC–PTX NPs are
safely administered at doses exceeding the LD50 of PTX-C/E. In
vivo, PGC–PTX NPs preferentially accumulate in IP tumors aer
local administration, similar to other negatively charged NPs.60
Furthermore, a single dose of PGC–PTX NPs exhibits an equiv-
alent oncologic effect to seven weekly doses of PTX-C/E,
rendering PGC–PTX NPs an ideal platform for increasing
patient compliance, reducing costs associated with visits, and
eliminating the use of C/E and its related toxicities. Notably,
PGC–PTX NPs present a unique drug delivery system for the
improvement and optimization of chemotherapeutic dosing
regimens by enabling the facile implementation of a high dose,
sustained release treatment platform.Conflicts of interest
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